Doxycycline (a tetracycline) reduces IL-6, IL-1β and TNF-α levels, however, doxycycline treatment did not have a significant clinical impact on time to recovery, hospital admissions or deaths related to COVID-19 in patients with high risk to adverse outcomes (101). This evidence concerns the gene IL1B and COVID-19.